AccessibilityHelpAbout Us
Clinuvel Pharmaceuticals logo

Clinuvel Pharmaceuticals(OTC) CLVLF

Market Cap$297.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+2,613%
5 Year-80%
1 Year-26%
1 Month-18%
$5.68
+0.00%
+0.00Today
Clinuvel Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 5.892026-09-21
Clinuvel Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 5.892026-09-04
1 month-18.49%USD 7.232026-08-19
3 month-2.85%USD 6.062026-06-10
Year to date-23.04%USD 7.652025-12-12
1 year-25.74%USD 7.932025-09-19
3 year-39.56%USD 9.752023-09-19
5 year-80.01%USD 29.462021-09-22
Since inception+2,613.44%USD 0.222003-06-24

Clinuvel Pharmaceuticals Financials at a Glance

Market Cap

$297.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$188.95M

Net Income (TTM)

A$70.05M

EPS (TTM)

$0.46

P/E Ratio

12.71

Dividend

$0.04

Beta (Volatility)

0.09 (Low)

Price

$5.68

Volume

860

Open

$5.68

Previous Close

$5.68

Daily Range

$5.68 - $5.68

52-Week Range

$5.68 - $8.60

Estimated Earnings Date

Feb 23, 2027

CLVLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company focused on developing and marketing innovative therapeutic solutions for patients with severe genetic and metabolic conditions. Established in 1987, the company operates globally, with a primary emphasis on its flagship product, SCENESSE, which provides photoprotection for individuals diagnosed with erythropoietic protoporphyria (EPP).

Products and Services
  • SCENESSE: A systemic photoprotective medication for EPP patients
  • CUV9900: An alpha-melanocyte stimulating hormone analogue in development
  • Parvysmelanotide (VLRX001): A compound enhancing cellular activity
Growth Outlook
  • Strategic partnership with HK Winhealth Pharma to expand in China
  • Strong pipeline with multiple promising compounds under development
  • Increasing global awareness of EPP may drive demand for SCENESSE
Financial Highlights
  • Recent quarterly revenue of AUD 57 million, reflecting strong market performance
  • Net income margin of 41% indicates robust profitability
  • Cash and short-term investments total AUD 251 million, ensuring liquidity
Clinuvel Pharmaceuticals Limited is well-positioned in the biotechnology sector, focusing on unmet medical needs. The company's commitment to innovation is evident in its diverse product pipeline, which aims to address severe conditions that currently lack effective treatments. The recent partnership with HK Winhealth Pharma is a strategic move to enhance market access in China, potentially increasing the patient base for SCENESSE. Financially, the company has demonstrated strong revenue growth and profitability, supported by a solid cash position that allows for continued investment in research and development. As the global awareness of EPP and related conditions grows, Clinuvel's innovative solutions may play a crucial role in improving patient outcomes.
AI Generated • Sep 16, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Philippe Jacques Wolgen, MD, MBA

Website

www.clinuvel.com

Headquarters

Melbourne, VIC 3000, AU

CLVLF Financials

Key Financial Metrics (TTM)

Gross Margin

43.11%

Operating Margin

43.11%

Net Income Margin

36.07%

Return on Equity

13.00%

Return on Capital

14.75%

Return on Assets

11.45%

Earnings Yield

7.87%

Dividend Yield

0.61%

Payout Ratio

7.39%

Stock Overview

Market Cap

$297.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.43M

Volume

860

Avg. Volume

1.06K

Financials (TTM)

Gross Profit

A$150.33M

Operating Income

A$84.33M

EBITDA

A$88.54M

Operating Cash Flow

A$77.97M

Capital Expenditure

-A$1.90M

Free Cash Flow

A$76.07M

Cash & ST Invst.

A$251.70M

Total Debt

A$1.94M

Clinuvel Pharmaceuticals Performance Analysis

Clinuvel Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 52,687,10410.5%
20242024-06-30AUD 57,789,8619.7%
20252025-06-30AUD 61,536,3236.5%
20262026-06-30AUD 63,713,0893.5%
Clinuvel Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-36.3%
Q42025-06-3066.5%
Q22025-12-31-37.8%
Q42026-06-3054.4%
Clinuvel Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD 0.4035.8%
20242024-06-30AUD 0.4615.2%
20252025-06-30AUD 0.471.6%
20262026-06-30AUD 0.45-2.6%
Clinuvel Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-42.9%
Q42025-06-3057.1%
Q22025-12-31-52.3%
Q42026-06-30123.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$57.01M

+2.0%

Gross Profit

A$56.39M

+37.6%

Gross Margin

98.91%

N/A

Market Cap

$297.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.72M

N/A

Employees

109

N/A

Net Income

A$23.44M

-5.1%

EBITDA

A$30.02M

-13.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$251.70M

+36.9%

Total Debt

A$1.94M

+120.0%

Accounts Receivable

A$23.42M

-10.7%

Inventory

A$6.87M

-35.3%

Long Term Debt

A$1.55M

+203.5%

Short Term Debt

A$388.07K

+4.9%

Return on Assets

11.45%

N/A

Return on Invested Capital

14.64%

N/A

Free Cash Flow

A$22.90M

+120.2%

Operating Cash Flow

A$24.35M

+128.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYDYCytoDyn Inc.
$0.23+10.62%
NWBONorthwest Biotherapeutics, Inc.
$0.16+0.50%
CMVLFCellectis S.A.
$3.47+12.66%
PTCHFPureTech Health plc
$1.54+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.54+3.55%
INTCIntel
$123.00-3.45%
NVDANvidia
$225.07+0.22%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.94-3.02%

Questions About CLVLF

What is the current price of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals is trading at $5.68 per share.

What is the 52-week range for Clinuvel Pharmaceuticals?

Over the past 52 weeks, Clinuvel Pharmaceuticals has traded between $5.68 and $8.60.

How much debt does Clinuvel Pharmaceuticals have?

As of the most recent reporting period, Clinuvel Pharmaceuticals reported total debt of A$1.34M.

How much cash does Clinuvel Pharmaceuticals have on hand?

Clinuvel Pharmaceuticals reported A$14.16M in cash and cash equivalents in its most recent financial results.

What is Clinuvel Pharmaceuticals’s dividend yield?

Clinuvel Pharmaceuticals currently has a dividend yield of 0.61%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services